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Epstein–Barr virus has been associated with a proportion of typical gastric adenocarcinomas. Here we report that the
prevalence of Epstein–Barr virus in gastric adenocarcinomas from the United Kingdom is one of the lowest in the World.
Gastric adenocarcinoma is another tumour whose association with Epstein–Barr virus varies with the population studied.
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An early report that the Epstein–Barr virus (EBV) was present in
the majority of lymphoepithelial-like carcinomas (LELCs) of the
stomach, a rare form of gastric neoplasia (Shibata et al, 1991),
was followed by the detection of EBV in 16% of typical gastric
adenocarcinomas (Shibata and Weiss, 1992). The subsequent ﬁnd-
ing of monoclonal EBV episomes (Imai et al, 1994; Ott et al, 1994)
and transforming proteins (zur Hausen et al, 2000) not only
suggested an aetiological role for this virus in these tumours, but
also the possibility that immunotherapy, for example CTL-based
anti-EBV therapies (Rooney et al, 1998) might prolong survival
for patients with virus-positive tumours. Before investing in such
a strategy it is necessary to determine the numbers of patients
who are likely to beneﬁt. Here we report the largest survey of
the prevalence of EBV in gastric adenocarcinomas undertaken
outside Asia.
MATERIALS AND METHODS
The base population comprised 497 consecutive patients who were
ﬁrst diagnosed with gastric adenocarcinoma between 1993–1999
and who had their tumours resected in one of three hospitals from
the West Midlands, UK. This series was supplemented by an addi-
tional 69 patients with unresected disease in whom the diagnosis
was made on gastric biopsy. Eight cases were excluded when histo-
pathological review could not conﬁrm the original diagnosis and
24 because there was insufﬁcient material for the preparation of
tissue arrays. EBV status was determined on the remaining 534
patients. All exclusions were from resected cases.
A 4 mm-diameter needle was used to sample representative
tumour areas from parafﬁn blocks using a modiﬁcation of the
method described by Kononen et al (1998). Twenty cylindrical
tumour cores were positioned in 5 mm holes cut from a
2.563 cm piece of parafﬁn-embedded liver tissue. Four micron
thick sections cut from the array were adhered to Vectabond
1
coated slides and in situ hybridisation for the detection of the
EBV-encoded RNAs (EBERs) performed according to standard
methods (Wu et al, 1990). Positive controls which included cores
from known EBV-positive gastric cancers were seeded into arrays.
Seventy-ﬁve which tested negative for EBERs in tissue arrays, were
re-evaluated by in situ hybridisation of the originating tissue
blocks. U6 and sense control probes were included in all runs
and assays were performed in duplicate.
RESULTS
The mean age of patients in this series was 65.4 years (range 34–87
years). The male to female ratio was 2.2:1. Among 465 patients
with resected disease 214 (46%) were classiﬁed as intestinal type
according to the criteria of Lauren (1965), 112 (24%) were diffuse,
108 (23%) mixed and 31 (7%) were unclassiﬁable. One hundred
and sixty-two (35%) of resected tumours involved the cardia,
289 (62%) the corpus/antrum, two (0.4%) the gastric stump and
in 12 (2.6%) subsite was unknown. EBERs were detected in 9
out of 534 (1.7%) tumours in eight patients with resected disease
and in one of those diagnosed on gastric biopsy. Both gastric
stump cancers were EBV-positive.
DISCUSSION
The prevalence of EBV-positive cancers in this series of gastric
adenocarcinomas is substantially less than that reported elsewhere
(Table 1). We believe this is not the result of sampling error in
the preparation of the tissue arrays because re-evaluation of
EBER-negative tumours using the originating tissue blocks revealed
no false-negatives and our ﬁndings are similar to those reported in
two smaller studies also undertaken in the UK which used tissue
blocks when testing for the presence of EBERs (Rowlands et al,
1993; Shousha and Luqmani, 1994).
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www.bjcancer.comAlthough a higher detection rate of EBV-positive tumours has
been reported in other European series, estimates are based on
comparatively small numbers of cancers with only 10 tumours in
total testing positive for EBV. No patient in our series was found
to have a LELC. These tumours are strongly associated with EBV
and both gastric LELC and LELCs at other sites are more common
in Asia (Gaffey and Weiss, 1990). The higher rate of detection of
EBV in gastric adenocarcinomas observed in large Asiatic series
suggests that gastric tumours are another site of cancer where
the strength of the association with EBV varies with the population
studied.
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Table 1 Prevalence of EBV in gastric adenoarcinomas
a
Number of gastric Number of EBV
+ gastric
Reference Country adenocarcinomas adenocarcinomas (%)
Tokunaga et al (1993b) Japan 1775 102 (5.7)
Imai et al (1994) Japan 991 62 (6.2)
Tokunaga et al (1993a) Japan 990 59 (5.9)
Burgess et al (present study) UK 534 9 (1.7)
Chang et al (2000) Korea 292 10 (3.4)
Galetsky et al (1997) Russia 206 18 (8.7)
Rowlands et al (1993) UK 117 UK 2 (1.7)
Japan 51 Japan 1 (2)
Qiu et al (1997) Japan 51 Japan 9 (6)
China 90 China 7 (7.8)
Shibata and Weiss (1992) USA 138 22 (16)
Wu et al (2000) Taiwan 139 19 (13.7)
Herrera-Goepfert et al (1999) Mexico 130 6 (4.6)
Moritani et al (1996) Japan 120 5 (4.2)
Yanai et al (1997) Japan 109 7 (6.4)
Yuen et al (1994) Hong Kong 71 6 (8.4)
Leoncini et al (1993) Italy 65 3 (4.6)
Harn et al (1995) Taiwan 54 5 (9.3)
Chapel et al (2000) France 52 4 (7.7)
Nakamura et al (1994) Japan 42 4 (9.5)
Ott et al (1994) Germany 35 3 (8.5)
Ohfuji et al (1996) Japan 23 0
Shousha and Luqmani (1994) UK 11 0
aLELC excluded, as were series in which LELC could not separately be distinguished from adenocarcinomas, includes
only series with 410 cases.
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